October 4, 2016
(STAT News) – Twelve years ago, a dotcom millionaire stood at a patient advocacy group’s board meeting and made an offer. I’ll give you $1 million, he said. But only if you commit to getting an artificial pancreas on the market. That challenge set JDRF, formerly known as the Juvenile Diabetes Research Foundation, on a costly, and risky, campaign to enlist academic researchers, global companies, members of Congress, and even federal regulators to embrace the concept of a device that could take over much of the process of regulating blood sugar in patients with diabetes.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.